Pharmacologic agents are commonly used to treat psychiatric diseases. These compounds, however, react differently across patients, are often followed by negative side effects and can have varied efficacy timeframes.
Selective cytotoxicity, or the ability to selectively remove certain cell types from a population, is a vital technology that is often applied to various therapeutic applications.
Stanford researchers in the Mark Davis Lab have developed a human cell culture system to grow 3D immune organoids within hydrogel structures using limited cellular input that can be adapted to large screening assays for flexible downstream immunological readouts.
Stanford researchers in the Khosla lab have invented a new class of "molecular glues" that couple the enzymatic activity of a cell-surface enzyme, transglutaminase 2 (TG2), with the ability of the LDL receptor-related protein 1 (LRP-1) to promote receptor-mediated endocytosis
Researchers in Prof. Brian Feldman's laboratory have developed a patented drug screen to identify compounds that could potentially treat obesity and metabolic disease by converting cells to calorie-burning brown fat.